Earnings History Data for Alkermes plc (ALKS) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Alkermes plc

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
15-02-2024	PM		ALKS	Alkermes plc	4,540	0.34	0.29	-0.02	Alkermes Non-GAAP EPS of $0.22 misses by $0.24, revenue of $377.5M beats by $15.13M [2/15/2024 7:07 AM]	32.59	4.60 (16.43%)	29.48	1.49 (5.32%)	22.01 - 33.71	4,808,421	1,590,000	537
Alkermes Q4 2023 Earnings Preview [2/14/2024 11:25 AM] Alkermes Non-GAAP EPS of $0.22 misses by $0.24, revenue of $377.5M beats by $15.13M [2/15/2024 7:07 AM]
25-10-2023	PM		ALKS	Alkermes plc	4,070	0.50	0.31	-0.14	Alkermes Non-GAAP EPS of $0.64 beats by $0.21, revenue of $380.94M beats by $18.74M [10/25/2023 7:05 AM]	23.50	-1.82 (-7.19%)	23.81	-1.51 (-5.96%)	22.01 - 33.71	3,456,413	2,160,000	5,292
Evercore ISI upgrades Alkermes to outperform, cites orexin potential [10/24/2023 2:15 PM] Alkermes Q3 2023 Earnings Preview [10/24/2023 12:11 PM] Alkermes Non-GAAP EPS of $0.64 beats by $0.21, revenue of $380.94M beats by $18.74M [10/25/2023 7:05 AM]
26-07-2023	PM		ALKS	Alkermes plc	5,280	0.38	0.28	-0.08	Alkermes Non-GAAP EPS of $0.55 misses by $0.09, revenue of $617.4M beats by $134.27M [7/26/2023 7:07 AM]	30.07	-0.77 (-2.50%)	32.60	1.76 (5.71%)	21.75 - 33.71	2,355,664	1,270,000	1,061
Alkermes Q2 2023 Earnings Preview [7/25/2023 2:12 PM] Alkermes Non-GAAP EPS of $0.55 misses by $0.09, revenue of $617.4M beats by $134.27M [7/26/2023 7:07 AM]
26-04-2023	PM	7:00 AM ET (Apr 26)	ALKS	Alkermes plc	4,800	-0.10	-0.19	0.01	Alkermes Non-GAAP EPS of $0.01 beats by $0.02, revenue of $287.6M beats by $6.41M [4/26/2023 7:04 AM]	28.39	-2.12 (-6.95%)	29.85	-0.66 (-2.16%)	21.75 - 32.79	2,134,825	1,800,000	1,551
Alkermes gets tribunal award in J&J license deal arbitration [4/25/2023 9:42 AM] Alkermes Non-GAAP EPS of $0.01 beats by $0.02, revenue of $287.6M beats by $6.41M [4/26/2023 7:04 AM]
16-02-2023	PM	7:00 AM ET (Feb 16)	ALKS	Alkermes plc	4,550	-0.02	-0.09	0.13	Alkermes Non-GAAP EPS of $0.14 beats by $0.09, revenue of $304.67M beats by $14.87M [2/16/2023 7:03 AM]	28.12	1.13 (4.19%)	30.00	3.01 (11.15%)	21.75 - 32.79	2,643,067	1,090,000	5,271
Alkermes Non-GAAP EPS of $0.14 beats by $0.09, revenue of $304.67M beats by $14.87M [2/16/2023 7:03 AM]
02-11-2022	PM	7:00 AM ET (Nov 2)	ALKS	Alkermes plc	3,730	-0.14	-0.13	-0.02	Alkermes Non-GAAP EPS of $0.02 misses by $0.01, revenue of $252.36M misses by $19.09M [11/2/2022 7:09 AM]	24.10	0.85 (3.66%)	25.01	1.76 (7.57%)	21.24 - 32.79	3,669,257	0	5,790
Alkermes Non-GAAP EPS of $0.02 misses by $0.01, revenue of $252.36M misses by $19.09M [11/2/2022 7:09 AM] Alkermes looking at splitting off oncology business into separate company [11/2/2022 10:11 AM] A Message on Corporate Responsibility From Richard F. Pops, Alkermes CEO [Nov-01-22 10:50AM]
27-07-2022	PM	7:00 AM ET (Jul 27)	ALKS	Alkermes plc	4,730	-0.08	-0.12	0.13	Alkermes Non-GAAP EPS of $0.06 beats by $0.05, revenue of $276.2M beats by $7.19M [7/27/2022 7:06 AM]	27.95	-1.44 (-4.90%)	29.50	0.11 (0.37%)	21.24 - 33.00	2,767,544	1,260,000	428
Alkermes Q2 2022 Earnings Preview [7/26/2022 12:09 PM] Alkermes Non-GAAP EPS of $0.06 beats by $0.05, revenue of $276.2M beats by $7.19M [7/27/2022 7:06 AM] Philips' (PHG) Q2 Earnings Down on Supply Chain Constraints [Jul-26-22 11:16AM] Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More [Jul-26-22 11:04AM] Alkermes plc Reports Second Quarter 2022 Financial Results [Jul-27-22 07:00AM]
27-04-2022	PM	7:00 AM ET (Apr 27)	ALKS	Alkermes plc	4,650	0.01	-0.14	0.01	Alkermes Non-GAAP EPS of $0.12 beats by $0.11, revenue of $278.5M beats by $22.48M [4/27/2022 7:04 AM]	30.40	3.26 (12.01%)	30.00	2.86 (10.54%)	21.17 - 33.00	3,420,599	1,570,000	2,217
Alkermes Q1 2022 Earnings Preview [4/26/2022 2:07 PM] Alkermes Non-GAAP EPS of $0.12 beats by $0.11, revenue of $278.5M beats by $22.48M [4/27/2022 7:04 AM] Alkermes stock rises 11% as Q1 revenue soars on the back of proprietary drugs Aristada, Vivitrol [4/27/2022 11:05 AM] Drug/Biotech Stocks' Apr 27 Q1 Earnings Roster: GSK, AMGN & More [Apr-26-22 11:44AM] Alkermes plc Reports First Quarter 2022 Financial Results [Apr-27-22 07:00AM] Alkermes (ALKS) Tops Q1 Earnings and Revenue Estimates [Apr-27-22 09:25AM] Alkermes Recognizes Minority Cancer Awareness Month [Apr-27-22 11:51AM] Alkermes (ALKS) Q1 2022 Earnings Call Transcript [Apr-27-22 12:01PM] IBD Stock Of The Day Alkermes Breaks Out As Its Newest Drug Snags Big Beat [Apr-27-22 12:25PM] Why Alkermes Stock Is Jumping Today [Apr-27-22 12:37PM] LGBTQ+ People Are More Likely to Experience a Mental Health Condition [Apr-27-22 04:56PM]
16-02-2022	PM	7:00 AM ET (Feb 16)	ALKS	Alkermes plc	3,730	0.13	0.02	-0.05	Alkermes Non-GAAP EPS of $0.23 beats by $0.10, revenue of $324.5M beats by $17.95M [2/16/2022 7:07 AM]	26.78	3.48 (14.91%)	23.40	0.09 (0.39%)	18.02 - 33.00	2,116,165	1,250,000	1,802
Alkermes Q4 2021 Earnings Preview [2/15/2022 11:23 AM] Alkermes Non-GAAP EPS of $0.23 beats by $0.10, revenue of $324.5M beats by $17.95M [2/16/2022 7:07 AM] Alkermes stock soars 13% as Q4 revenue rises 16% Y/Y; provides FY22, long term outlook [2/16/2022 11:49 AM] Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022 [Feb-16-22 07:00AM] Alkermes (ALKS) Q4 Earnings and Revenues Beat Estimates [Feb-16-22 08:55AM] Results From The Harris Poll and Depression and Bipolar Support Alliance [Feb-16-22 02:00PM] Why Alkermes Stock Blasted 15% Higher Today [Feb-16-22 05:26PM]
27-10-2021	PM	7:00 AM ET (Oct 27)	ALKS	Alkermes plc	4,980	-0.02	-0.05	0.12	Alkermes EPS beats by $0.04, misses on revenue [10/27/2021 7:28 AM]	28.65	-2.86 (-9.08%)	28.65	0.0 (0.00%)	15.35 - 33.00	2,579,024	1,070,000	16,451
Alkermes Q3 2021 Earnings Preview [10/26/2021 12:32 PM] Alkermes initiates late-stage nemvaleukin combo ovarian cancer study [10/26/2021 7:57 AM] Alkermes EPS beats by $0.04, misses on revenue [10/27/2021 7:28 AM] Alkermes shares slide after Q3 topline miss [10/27/2021 10:41 AM] Repligen (RGEN) to Report Q3 Earnings: What's in the Cards? [Oct-26-21 10:56AM] Should You Buy Alkermes (ALKS) Ahead of Earnings? [Oct-26-21 08:46AM] Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer [Oct-26-21 07:00AM] Alkermes plc Reports Third Quarter 2021 Financial Results [Oct-27-21 07:00AM] Alkermes (ALKS) Beats Q3 Earnings Estimates [Oct-27-21 08:35AM] Alkermes plc (ALKS) Q3 2021 Earnings Call Transcript [Oct-27-21 04:00PM]
28-07-2021	PM	7:00 AM ET (Jul 28)	ALKS	Alkermes plc	3,910	0.13	-0.02	-0.08	Alkermes EPS beats by $0.18, beats on revenue [7/28/2021 7:09 AM]	25.77	1.63 (6.75%)	25.77	0.0 (0.00%)	15.35 - 25.91	1,605,798	1,310,000	456
Alkermes Q2 2021 Earnings Preview [7/27/2021 10:40 AM] Alkermes EPS beats by $0.18, beats on revenue [7/28/2021 7:09 AM] Alkermes plc Reports Second Quarter 2021 Financial Results [Jul-28-21 07:00AM] Alkermes (ALKS) Q2 Earnings and Revenues Beat Estimates [Jul-28-21 08:35AM]
28-04-2021	PM	7:00 AM ET (Apr 28)	ALKS	Alkermes plc	3,580	0.01	-0.21	-0.09	Alkermes EPS beats by $0.12, beats on revenue [4/28/2021 7:08 AM]	21.79	-0.71 (-3.16%)	22.00	-0.50 (-2.22%)	13.03 - 23.92	1,497,795	1,610,000	1,466
Alkermes Q1 2021 Earnings Preview [4/27/2021 12:46 PM] Alkermes EPS beats by $0.12, beats on revenue [4/28/2021 7:08 AM] Alkermes shares rise on Q1 earnings beat [4/28/2021 8:08 AM] Alkermes Launches New Disease State Website to Offer Education About Alcohol Dependence [Apr-27-21 04:01PM] Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma [Apr-27-21 07:00AM] Alkermes Plc to Host Earnings Call [Apr-28-21 06:15AM] Alkermes plc Reports First Quarter 2021 Financial Results [Apr-28-21 07:00AM] Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting [Apr-28-21 07:05AM] Alkermes (ALKS) Q1 Earnings and Revenues Beat Estimates [Apr-28-21 08:45AM]
11-02-2021	PM	7:00 AM ET (Feb 11)	ALKS	Alkermes plc	3,670	-0.05	-0.04	0.69	Alkermes EPS beats by $0.03, beats on revenue [2/11/2021 7:07 AM]	20.10	-2.84 (-12.36%)	22.71	-0.22 (-0.96%)	11.98 - 23.92	3,344,403	1,295,882	1,880
Alkermes EPS beats by $0.03, beats on revenue [2/11/2021 7:07 AM] Alkermes Q4 2020 Earnings Preview [2/10/2021 12:28 PM] Alkermes Q4 topline slumps, provides 2021 forecast [2/11/2021 8:19 AM]
29-10-2020	PM	7:00 AM ET (Oct 29)	ALKS	Alkermes plc	2,530	0.12	-0.14	-0.22	Alkermes EPS beats by $0.26, beats on revenue [10/29/2020 7:06 AM]	16.28	0.89 (5.78%)	16.10	0.71 (4.61%)	11.98 - 21.88	1,897,850	1,054,901	4,409

29-07-2020	PM	7:00 AM ET (Jul 29)	ALKS	Alkermes plc	3,280	-0.08	-0.13	-0.06	Alkermes EPS beats by $0.06, beats on revenue [7/29/2020 7:02 AM]	19.84	-0.34 (-1.71%)	20.20	0.02 (0.10%)	11.98 - 23.50	1,195,754	1,610,133	306